Lv01
0 积分 2023-12-20 加入
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
1小时前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
1小时前
已完结
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
1小时前
已完结
The tumor-intrinsic role of the m 6 A reader YTHDF2 in regulating immune evasion
1个月前
已完结
Biselective remodeling of the melanoma tumor microenvironment prevents metastasis and enhances immune activation in mouse models
1个月前
已完结
PD-1–targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer
1个月前
已完结
Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
2个月前
已完结
Tetrahydromagnolol induces autophagic cell death by targeting the m6A reader protein YTHDF2 and enhances the efficacy of anti-PD-1 immunotherapy in pancreatic cancer cells
2个月前
已完结
Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2- Breast Cancer
2个月前
已完结
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
2个月前
已完结
皖公网安备34019202002308
